Naoki Katsuhiko, Chen Tzu-Hsiu, Richards William G, Sugarbaker David J, Meyerson Matthew
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Cancer Res. 2002 Dec 1;62(23):7001-3.
Mutations of the BRAF protein serine/threonine kinase gene have recently been identified in a variety of human cancers, most notably melanomas. We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis. Analysis of BRAF sequence from 127 primary human lung adenocarcinomas revealed mutations in two tumor specimens, one in exon 11 (G465V), and a second in exon 15 (L596R). These specimens belong to the same adenocarcinoma subgroup as defined by clustering of gene expression data. BRAF may provide a target for anticancer chemotherapy in a subset of lung adenocarcinoma patients.
BRAF蛋白丝氨酸/苏氨酸激酶基因突变最近在多种人类癌症中被发现,最显著的是黑色素瘤。我们试图确定BRAF突变在人类肺癌发病机制中的频率。对127例原发性人类肺腺癌的BRAF序列分析显示,两个肿瘤标本存在突变,一个在第11外显子(G465V),另一个在第15外显子(L596R)。这些标本属于根据基因表达数据聚类定义的同一腺癌亚组。BRAF可能为一部分肺腺癌患者的抗癌化疗提供靶点。